Olema Oncology: on track for palazestrant OPERA-01 Phase 3 topline in Q1 2027
Ang quarterly update na ito ay muling nagpapatunay na ang pivotal Phase 3 OPERA-01 trial ng palazestrant ay nananatiling on track upang iulat ang top-line data sa Q1 2027. Itinatala rin nito ang patuloy na malakas na enrollment sa pivotal Phase 3 OPERA-02 trial ng palazestrant plus ribociclib.
EX-99.1
2
olma-ex99_1.htm
EX-99.1
EX-99.1
Exhibit 99.1
Olema Oncology Reports Third Quarter 2026 Financial and Operating Results
• On track to announce top-line data from the pivotal Phase 3 OPERA-01 trial in the first quarter of 2027
• Continued strong enrollment in the pivotal Phase 3 OPERA-02 trial and the Phase 1b/2 study of OP-3136
• Appointed Jason O’Byrne, MBA, as Chief Financial Officer
• Ended the third quarter with $413.8 million in cash, cash equivalents, and marketable securities
SAN FRANCISCO, November 10, 2026 (Globe NewsWire) – Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today reported